Published in Clin Cancer Res on March 31, 2015
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomark Cancer (2016) 0.92
Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials. BMC Urol (2016) 0.79
Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience. BMC Urol (2016) 0.78
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. Ther Adv Med Oncol (2016) 0.77
Prostate cancer: PSA kinetics predict survival in patients treated with abiraterone. Nat Rev Urol (2015) 0.75
First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel. Front Pharmacol (2017) 0.75
Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet. Target Oncol (2017) 0.75
PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. Medicine (Baltimore) (2017) 0.75
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res (2014) 0.87
Challenges in treating patients with advanced urologic cancers. Curr Opin Support Palliat Care (2014) 0.75
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clin Cancer Res (2017) 0.75